Chronic lymphocytic leukemia: a clinical review

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in the US.
• CLL diagnosis impacts 15,000 individuals annually, with 5,000 deaths.
• Recent advancements have significantly improved therapeutic options for CLL.

Purpose of the Study:

• To provide an evidence-based review of CLL diagnosis, staging, and treatment.
• To analyze current treatment strategies and outcomes for CLL patients.

Main Methods:

• A comprehensive literature search was conducted using PubMed, Cochrane Library, Scopus, and Google Scholar.
• 24 peer-reviewed articles published between 2000-2014 were selected based on predefined criteria.
• Treatment recommendations were derived from the analysis of these selected studies.

Main Results:

• Current staging systems (Rai, Binet) do not fully encompass new CLL classifications like monoclonal B-cell lymphocytosis.
• Risk stratification now includes molecular and cytogenetic analyses, identifying distinct CLL subsets.
• Chemoimmunotherapy as first-line treatment yields response rates of 75-90%, with 3-year survival exceeding 80% and 5-year survival at 66%.

Conclusions:

• Chemoimmunotherapy is the established standard first-line treatment for symptomatic chronic lymphocytic leukemia.
• Initiating treatment upon symptom onset leads to significantly improved patient survival.
• Advances in therapy have markedly enhanced outcomes for adults diagnosed with CLL.